| Hughes, Derralynn |
| Active, not recruiting | 1/2 | 34 | Europe, Canada, US, RoW | ST-920 | Sangamo Therapeutics | Fabry Disease | 04/25 | 09/25 | | |
NCT05487599: A Clinical Trial of PR001 (LY3884961) in Patients with Peripheral Manifestations of Gaucher Disease (PROCEED) |
|
|
| Recruiting | 1/2 | 15 | Europe, US | LY3884961 | Prevail Therapeutics, Eli Lilly and Company | Gaucher Disease, Gaucher Disease, Type 1 | 10/30 | 10/30 | | |
| Active, not recruiting | 1 | 18 | Europe, US, RoW | FLT201 | Freeline Therapeutics, Freeline Therapeutics Limited | Gaucher Disease, Type 1 | 12/24 | 01/25 | | |
| Mandal, Swapna |
NCT04495062: The Use of Wearable Technology to Acquire Signals for COPD Research |
|
|
| Completed | N/A | 63 | Europe | | Royal Free Hospital NHS Foundation Trust, Imperial College London, Acurable Ltd. | Pulmonary Disease, Chronic Obstructive | 08/23 | 08/23 | | |
NCT05167201: Domiciliary Nasal High Flow and Patient Outcomes in Chronic Hypercapnic Respiratory Failure in the United Kingdom |
|
|
| Active, not recruiting | N/A | 54 | Europe | Nasal High Flow | Royal Free Hospital NHS Foundation Trust, Fisher and Paykel Healthcare, Royal Free Charity | Chronic Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Obesity Hypoventilation Syndrome (OHS), Nasal High Flow, Health-related Quality of Life | 01/24 | 01/24 | | |
NCT06097949: AcuPebble to Remotely Monitor Patients With OSA on CPAP Therapy |
|
|
| Recruiting | N/A | 25 | Europe | AcuPebble SA100 | Royal Free Hospital NHS Foundation Trust, Acurable Ltd. | Sleep Apnea, Obstructive | 02/24 | 02/24 | | |
| Goldstein, Robert |
| Active, not recruiting | 3 | 308 | Europe, Japan, US, RoW | carboplatin, paclitaxel, retifanlimab, INCMGA00012 | Incyte Corporation | Squamous Cell Carcinoma of the Anal Canal | 04/24 | 03/26 | | |
|
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
| Denton, Christopher |
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis |
|
|
| Active, not recruiting | 2/3 | 301 | Europe, Japan, US, RoW | HZN-825 BID, Placebo, HZN-825 QD | Amgen, Horizon Therapeutics USA, Inc | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 09/25 | 09/25 | | |
|
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
| Contact, Central |
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy |
|
|
| Completed | 4 | 52 | RoW | Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT) | Astellas Pharma Inc | Metastatic Castration Resistant Prostate Cancer | 02/24 | 02/24 | | |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants |
|
|
| Completed | 3 | 395 | RoW | Enzalutamide, Xtandi, MDV3100, Placebo | Astellas Pharma Inc | Progressive Metastatic Prostate Cancer | 09/15 | 07/24 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Recruiting | 3 | 177 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 09/27 | 09/27 | | |
NCT06617897: Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery |
|
|
| Recruiting | 3 | 90 | Europe | CSL511 Fibrinogen concentrate (human), Cryoprecipitate | CSL Behring | Acquired Fibrinogen Deficiency | 09/26 | 10/26 | | |
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study ) |
|
|
| Terminated | 3 | 1370 | Europe, US, RoW | BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo | CSL Behring | Traumatic Injury | 10/24 | 10/24 | | |
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 152 | RoW | Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA) | Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer | Solid Tumors, Colorectal Cancer | 04/18 | 09/18 | | |
| Active, not recruiting | 2 | 100 | US | ALG-055009, Placebo | Aligos Therapeutics | NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis | 11/24 | 12/24 | | |
NCT06545916: Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder |
|
|
| Recruiting | 2 | 200 | US | Sunobinop, V117957, Placebo to match sunobinop | Imbrium Therapeutics, Purdue Pharma LP | Alcohol Use Disorder | 07/25 | 07/25 | | |
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome |
|
|
| Completed | 1 | 47 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Interstitial Cystitis/Bladder Pain Syndrome | 01/25 | 01/25 | | |
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease |
|
|
| Completed | 1 | 28 | Europe, US | CSL889 | CSL Behring | Sickle Cell Disease | 07/23 | 07/23 | | |
| Recruiting | 1 | 174 | US | PRL-02 injection, prednisone, dexamethasone, enzalutamide | Astellas Pharma Global Development, Inc. | Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | 08/25 | 05/29 | | |
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors |
|
|
| Recruiting | 1 | 175 | US | ASP4396 | Astellas Pharma Inc | Solid Tumor | 04/27 | 04/27 | | |
| Recruiting | 1 | 229 | US | ASP1012, Pembrolizumab | Astellas Pharma Global Development, Inc. | Solid Tumor | 06/29 | 06/29 | | |
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas |
|
|
| Terminated | 1 | 1 | RoW | ASP2802, MACT, MA-20, ASP101G, MicAbody | Astellas Pharma Global Development, Inc. | B-cell Lymphoma | 12/24 | 12/24 | | |
NCT06024642: Study of V117957 in Overactive Bladder Syndrome |
|
|
| Completed | 1 | 51 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Overactive Bladder Syndrome | 05/24 | 05/24 | | |
| Completed | N/A | 1443 | US | | Shire | Hunter Syndrome | 02/23 | 02/23 | | |
| Recruiting | N/A | 1257 | US | | Shire | Gaucher Disease | 09/25 | 09/25 | | |
NCT06734585: Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant |
|
|
| Recruiting | N/A | 200 | RoW | Gilteritinib, ASP2215, XOSPATA® | Astellas Pharma Singapore Pte. Ltd. | Acute Myeloid Leukemia | 06/25 | 06/25 | | |
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats |
|
|
| Recruiting | N/A | 1000 | US | Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above | Astellas Pharma Global Development, Inc. | Hot Flashes | 02/26 | 11/26 | | |
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis |
|
|
| Recruiting | N/A | 3000 | Japan | Peficitinib, ASP015K, Smyraf | Astellas Pharma Inc | Rheumatoid Arthritis (RA) | 12/25 | 12/25 | | |
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens |
|
|
| Active, not recruiting | N/A | 249 | RoW | Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens | HOYA Lens Thailand LTD. | Myopia | 05/26 | 05/27 | | |
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection |
|
|
| Recruiting | N/A | 202 | RoW | Enfortumab Vedotin, PADCEV, ASG-22CE | Astellas Pharma Korea, Inc., Seagen Inc. | Urothelial Cancer | 07/27 | 07/27 | | |
| Manager, Project |
| Recruiting | 3 | 4514 | US | nasal antimicrobial photodisinfection therapy | Ondine Biomedical Inc. | Surgical Site Infections, Surgical Wound Infection, Infections, Anti-Infective Agents | 07/25 | 08/25 | | |
| Recruiting | 2 | 81 | Europe, US, RoW | Danvatirsen, ISIS 481464, AZD9150, Pembrolizumab, Keytruda | Flamingo Therapeutics NV | HNSCC | 05/25 | 05/26 | | |
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 1100 | Europe | Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole | Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation | ER+ Breast Cancer, HER2-negative Breast Cancer | 09/27 | 09/30 | | |
| Recruiting | 1/2 | 403 | US | FMC-376 | Frontier Medicines Corporation | Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, KRAS G12C, Pancreatic Cancer | 10/27 | 04/28 | | |
NCT05450549: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants |
|
|
| Completed | 1 | 47 | Europe | DNL919, Placebo | Denali Therapeutics Inc., Takeda | Healthy Participant | 06/23 | 06/23 | | |
MV371 LAI FiH, NCT06558643: Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants |
|
|
| Recruiting | 1 | 24 | Europe | MMV371 LAI, Placebo for MMV371 | Medicines for Malaria Venture, Quotient Sciences, The Doctors Laboratory | Malaria,Falciparum | 03/25 | 03/25 | | |
NCT06639724: Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer |
|
|
| Recruiting | 1 | 36 | US | Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) | University of California, San Diego, Rigel Pharmaceuticals | Pancreatic Ductal Adenocarcinoma (PDAC) | 06/27 | 12/28 | | |
NCT06812117: A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study) |
|
|
| Recruiting | N/A | 720 | RoW | No Drug | Daiichi Sankyo | Diabetic Peripheral Neuropathic Pain | 02/26 | 04/26 | | |
RERUN, NCT06809764: Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC |
|
|
| Not yet recruiting | N/A | 150 | RoW | No drug | Daiichi Sankyo | Non-small Cell Lung Cancer | 02/27 | 02/27 | | |
| Recruiting | N/A | 400 | Europe | ctDNA | Royal Marsden NHS Foundation Trust, Massachusetts General Hospital, Natera, Inc. | Breast Cancer | 12/25 | 12/28 | | |
| Aissa, Myriam Ait |
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis |
|
|
| Active, not recruiting | 2/3 | 301 | Europe, Japan, US, RoW | HZN-825 BID, Placebo, HZN-825 QD | Amgen, Horizon Therapeutics USA, Inc | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 09/25 | 09/25 | | |
|
| Chowdary, Pratima |
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial |
|
|
| Terminated | 3 | 15 | RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor | 01/25 | 01/25 | | |
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B |
|
|
| Active, not recruiting | 2 | 60 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B | 11/24 | 02/25 | | |
| Terminated | N/A | 108 | Europe, Canada, US, RoW | No Intervention | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B | 11/24 | 11/24 | | |
| Thorburn, Douglas |
| Active, not recruiting | 3 | 238 | Europe, Canada, Japan, US, RoW | Linerixibat, Placebo | GlaxoSmithKline | Pruritus | 10/24 | 01/25 | | |
| Recruiting | 3 | 251 | Europe, Canada, Japan, US, RoW | Linerixibat | GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited | Cholestasis | 02/27 | 02/27 | | |
| Active, not recruiting | 2 | 68 | Europe, US, RoW | Anti-human CCL24 monoclonal antibody (CM-101), Placebo | ChemomAb Ltd., ChemomAb Ltd | Primary Sclerosing Cholangitis | 09/24 | 09/25 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
| Ishii, Tomonori |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis |
|
|
| Active, not recruiting | 2/3 | 301 | Europe, Japan, US, RoW | HZN-825 BID, Placebo, HZN-825 QD | Amgen, Horizon Therapeutics USA, Inc | Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | 09/25 | 09/25 | | |
|
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
| Tsui, Janice |
| No trials found |
| Phillips, Mark |
| No trials found |
